TY - JOUR
T1 - Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy
AU - Farah, Ramez
AU - Golomb, Harvey M.
AU - Hallahan, Dennis E.
AU - Desser, Richard K.
AU - Griem, Melvin L.
AU - Blough, Richard
AU - Ultmann, John E.
AU - Weichselbaum, Ralph R.
N1 - Funding Information:
Medical Center. Department of Radiation and Cellular Oncology, 5841 S. Maryland Avenue, Box 442, Chicago, IL 60637. Acknowledgements-Supported in part by The University of Chicago Cancer Research Center; Public Health Service Grant No. 2P30 CA-14599-o 1-15, National Cancer Institute, National Institutes of Health, DHHS; The Beverly Duchossois Cancer Research Fund; and Julie Rosenthal Linker Cancer Research Foundation. Accepted for publication 13 April 1989.
PY - 1989/10
Y1 - 1989/10
N2 - Ninety-eight patients with pathological Stage (PS) III Hodgkin's disease treated between 1969 and 1984 were retrospectively analyzed. Treatment consisted of radiation therapy (RT) alone in 46 patients and combined radiation therapy and chemotherapy (CMT) in 52 patients. The median follow-up was 10 years (range 3-19 years). Fifteen-year survival for patients with Stage III1 is better than for Stage III2 patients (82% vs 53%; p = .014). Patients with Stage III1A have a favorable prognosis regardless of treatment modality. The probability of freedom from relapse at 15 years for patients with pathological Stage III1A treated with radiation therapy is 70%, compared to 83% for pathological Stage III1A patients treated with combined modality therapy (p = .56). In patients with pathological Stage III2A, III1B, and III2B relapses were less frequent with the use of combined modality therapy compared to radiation therapy. We conclude that pathological Stage III1A patients may be treated with radiation therapy alone; the other subsets of patients benefit from combined radiation and chemotherapy.
AB - Ninety-eight patients with pathological Stage (PS) III Hodgkin's disease treated between 1969 and 1984 were retrospectively analyzed. Treatment consisted of radiation therapy (RT) alone in 46 patients and combined radiation therapy and chemotherapy (CMT) in 52 patients. The median follow-up was 10 years (range 3-19 years). Fifteen-year survival for patients with Stage III1 is better than for Stage III2 patients (82% vs 53%; p = .014). Patients with Stage III1A have a favorable prognosis regardless of treatment modality. The probability of freedom from relapse at 15 years for patients with pathological Stage III1A treated with radiation therapy is 70%, compared to 83% for pathological Stage III1A patients treated with combined modality therapy (p = .56). In patients with pathological Stage III2A, III1B, and III2B relapses were less frequent with the use of combined modality therapy compared to radiation therapy. We conclude that pathological Stage III1A patients may be treated with radiation therapy alone; the other subsets of patients benefit from combined radiation and chemotherapy.
KW - Combined modality therapy
KW - Radiation therapy
KW - Stage III Hodgkin's disease
UR - http://www.scopus.com/inward/record.url?scp=0024744123&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(89)90063-1
DO - 10.1016/0360-3016(89)90063-1
M3 - Article
C2 - 2777665
AN - SCOPUS:0024744123
SN - 0360-3016
VL - 17
SP - 761
EP - 766
JO - International journal of radiation oncology, biology, physics
JF - International journal of radiation oncology, biology, physics
IS - 4
ER -